Clin Chem Lab Med. 2015 May;53(6):863-70. doi: 10.1515/cclm-2014-1142.
The aims of this study are: 1) to use the data included in the biological variation (BV) database to address the usability of BV estimates; and 2) to use different examples from the authors' laboratories to illustrate the use and the usefulness of BV data in laboratory medicine. The BV database is an essential tool for laboratory management. Examples of application of data derived from BV are given in this paper, such as analytical performance specifications that have been included in various quality control software designed to optimize operative rules; also they have been incorporated as acceptability limits in external quality assurance reports. BV data from pathological status are of utmost interest for monitoring patients and differences between the intra-individual coefficients of variation (CVI) estimated from healthy and patients are shown. However, for a number of analytes there are limited data available and for many there are no data, consequently new studies should be encouraged at an international level. In addition, developing international criteria to evaluate publications dealing with the estimation of BV components would be of the utmost interest. We are ready and willing to collaborate with such worthy initiatives. The first EFLM strategic conference on analytical performance specifications is an excellent opportunity for debating these ideas.
1）利用生物变异（BV）数据库中的数据来解决 BV 估计的可用性问题；2）使用作者实验室的不同示例来说明实验室医学中 BV 数据的用途和实用性。BV 数据库是实验室管理的重要工具。本文给出了从 BV 数据中得出的应用示例，例如已包含在各种旨在优化操作规则的质量控制软件中的分析性能规格；它们也已作为可接受性限制纳入外部质量保证报告。病理状态下的 BV 数据对于监测患者非常重要，并且还显示了从健康个体和患者中估计的个体内变异系数（CVI）之间的差异。然而，对于许多分析物，可用的数据有限，对于许多分析物则没有数据，因此应鼓励在国际层面开展新的研究。此外，制定评估涉及 BV 成分估计的出版物的国际标准将是最感兴趣的。我们已经准备好并愿意与这些有价值的倡议合作。第一届 EFLM 分析性能规格战略会议是讨论这些想法的绝佳机会。
